SYDNEY, 30 May 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to announce that the DARRT-1 study, investigating Veyonda in combination with low dose external beam radiotherapy in men with late-stage, metastatic, castration-resistant prostate cancer (mCRPC), has completed enrolment. This is the company’s first clinical study of the Company’s external beam radio-enhancement program (DARRT).
Final patient enrolled into study
Topline data to be announced in Q4 2019
For further information please download the attached PDF:
Download this document